Trial · NCT01147666
Participant flow150
How many started, completed or left each group, period by period.
101 to 120 of 150
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dosing Period 2: 19-Week Treatment | Received at Least 1 Dose of Study Drug | Cohorts A (Epoetin Alfa) | 23 | |
| Dosing Period 2: 19-Week Treatment | Received at Least 1 Dose of Study Drug | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | 0 | |
| Dosing Period 2: 19-Week Treatment | Received at Least 1 Dose of Study Drug | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | 5 | |
| Dosing Period 2: 19-Week Treatment | Received at Least 1 Dose of Study Drug | Cohort B (Epoetin Alfa) | 3 | |
| Dosing Period 2: 19-Week Treatment | Received at Least 1 Dose of Study Drug | Cohort B (Placebo) | 3 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-1 (Roxadustat 1.0 mg/kg TIW) | 0 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-2 (Roxadustat 1.5 mg/kg TIW) | 0 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-3 (Roxadustat 2.0 mg/kg TIW) | 0 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-4 (Roxadustat 1.8 mg/kg TIW) | 6 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-5 (Roxadustat 1.8 mg/kg TIW) | 11 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-6 (Roxadustat 1.3 mg/kg TIW) | 11 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg) | 11 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg) | 10 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-9 (Roxadustat 2.0 mg/kg) | 2 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg) | 10 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohorts A (Epoetin Alfa) | 22 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort B-1 (Roxadustat 1.5 mg/kg TIW) | 0 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort B-2 (Roxadustat 2.0 mg/kg TIW) | 3 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort B (Epoetin Alfa) | 3 | |
| Dosing Period 2: 19-Week Treatment | EE Population for 19-week Treatment | Cohort B (Placebo) | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01147666/flow?page=6